REGN Regeneron Pharmaceuticals, Inc.
Healthcare$634.62-0.67%ClosedMarket Cap: $65.38B
As of 2026-05-26
Valuation
P/E (TTM)
17.54
PEG
8.38
P/B
2.11
P/S
4.41
EV/EBITDA
11.41
DCF Value
$2,118.41
FCF Yield
6.3%
Div Yield
0.6%
Margins & Returns
Gross Margin
84.5%
Operating Margin
24.3%
Net Margin
29.6%
ROE
14.3%
ROA
10.8%
ROIC
8.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $3.61B | 81.4% | $642.9M | $727.2M | $— | $0.94 |
| Q4 null | $3.88B | 84.9% | $879.9M | $844.6M | $— | $0.88 |
| FY null | $14.34B | 85.4% | $3.58B | $4.50B | $— | $3.52 |
| Q3 null | $3.75B | 86.1% | $1.03B | $1.46B | $— | $0.88 |
| Q2 null | $3.68B | 85.6% | $1.08B | $1.39B | $— | $0.88 |
| Q1 null | $3.03B | 84.7% | $591.7M | $808.7M | $— | $0.88 |
| Q4 null | $3.79B | 85.1% | $990.2M | $917.7M | $— | — |
| FY null | $14.20B | 86.1% | $3.99B | $4.41B | $— | — |
| Q3 null | $3.72B | 86.8% | $1.18B | $1.34B | $— | — |
| Q2 null | $3.55B | 86.5% | $1.07B | $1.43B | $— | — |
| Q1 null | $3.15B | 86.2% | $751.4M | $722.0M | $— | — |
| Q4 2023 | $3.43B | 81.7% | $1.05B | $1.16B | $10.19 | — |